aurobindo pharma delivered resilient financial performance in FY26, reporting a 2.2% year-on-year increase in standalone revenue to ₹111,717 million. The Hyderabad-based pharmaceutical giant saw its consolidated revenue grow by 6.1% to ₹336,531 million, underpinned by robust demand in European markets and strategic portfolio expansion. Despite headwinds in the US market, the company maintained EBITDA margins above 20%, reflecting disciplined cost management and operational efficiency. This growth trajectory reinforces Aurobindo’s position as the largest generic pharma company in the US by prescriptions dispensed and the third-largest listed Indian pharma company by revenue.

The Board of Directors declared an interim dividend of 400% (₹4.00 per equity share) during the year but did not recommend a final dividend for FY26. The company also completed a buyback of 5,423,728 equity shares for an aggregate value of ₹8,000 million, reducing paid-up capital to ₹58,08,01,623. These shareholder returns highlight management’s confidence in cash flow generation and long-term value creation amidst a complex global regulatory landscape.

Business Segment Performance

Geographic diversification remained a key driver of financial resilience, with 91% of revenues originating from international markets. Europe emerged as the standout performer, crossing the significant milestone of €1 billion in annual revenues. In contrast, the US business faced industry-wide pressures, resulting in a slight decline.

The Active Pharmaceutical Ingredients (API) business declined 6.4% to ₹40,469 million, reflecting softer demand in certain segments. However, the Antiretroviral (ARV) formulations segment posted strong growth of 33.5%, supported by the South Africa tender valued at over USD 90 million.

Financial Highlights

Aurobindo Pharma’s profitability metrics demonstrated stability despite mixed volume trends across regions. Profit Before Depreciation, Interest, Tax and Exceptional Items stood at ₹73,393 million, a 2.3% increase year-on-year. The company reported a Net Profit After Tax of ₹35,030 million, compared to ₹34,836 million in FY25. Diluted Earnings Per Share rose to ₹60.34 from ₹59.81 in the prior year.

Capital deployment focused on strengthening manufacturing infrastructure and backward integration. Total capital expenditure for FY26 was ₹3,058 million (USD ~340 million). Investments included new mammalian drug substance manufacturing capacity for biosimilars, with an incremental investment of USD 150–175 million planned for future phases.

What the Numbers Show

The divergence between US and European performance highlights the shifting dynamics in global generic markets. While the US faced pricing pressures and regulatory scrutiny, Europe benefited from portfolio expansion and reliable supply capabilities. The surge in ARV revenues underscores the company’s strategic importance in global health initiatives. Additionally, the consistent EBITDA margin above 20% indicates that Aurobindo is successfully leveraging scale and operational efficiencies to protect profitability even as revenue growth moderates in key markets like the US and APIs.

Aurobindo Pharma Limited will host an analyst and investor call on August 6, 2026, at 8:30 AM IST to discuss its unaudited financial results for the first quarter ended June 30, 2026. The event provides stakeholders with an opportunity to review the company’s performance in Q1FY27 and address queries regarding operational and financial outcomes. This disclosure ensures timely access to material information for investors and market participants following the release of quarterly earnings.

The announcement was made pursuant to Regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted the schedule to the Listing Department of the National Stock Exchange of India Limited and the Corporate Relations Department of BSE Limited. B. Adi Reddy, Company Secretary, digitally signed the communication on July 29, 2026.

Call Details

Participants can join the earnings call through Zoom by pre-registering via the provided link or accessing the session directly through the browser. The earnings presentation will be available on the company’s website after the results announcement.

Regulatory Compliance

The notice was issued to ensure compliance with listing obligations under SEBI regulations. The company code for Aurobindo Pharma Limited is AUROPHARMA on NSE and 524804 on BSE. The corporate office is located in Hyderabad Knowledge City, Ranga Reddy District, Telangana, while the registered office is situated in Ameerpet, Hyderabad.

What This Means for Investors

The earnings call serves as a critical channel for management to contextualize the Q1FY27 financial data. Investors should note that the discussion will focus on unaudited figures, which may be subject to revision upon final audit. The availability of the presentation post-call allows for detailed analysis of segment performance and key metrics disclosed during the quarter.